dra. arpana verma mesa pacap
TRANSCRIPT
![Page 1: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/1.jpg)
Measures to improve COPD outcomes in Greater Manchester: a multimodal approach
Dr Arpana Verma, Annie HarrisonManchester Urban Collaboration on HealthManchester Academic Health Sciences CentreUniversity of Manchester, UK
![Page 2: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/2.jpg)
Overview
• Setting the scene– Urban health– Who are we
– Rationale for studying COPD• The three studies• Conclusions
![Page 3: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/3.jpg)
Setting the scene
• Greater Manchester– Conurbation of 10 areas– Population 2.6 million– Deprivation– Industrial past and present
![Page 4: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/4.jpg)
Greater Manchester
Index of Multiple
Deprivation Score 2007
![Page 5: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/5.jpg)
Where is this?
![Page 6: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/6.jpg)
www.gapminder.org• Prof Hans Rosling and Google• Free to use “fact tank” • Credit Gapminder as the source
• www.bit.ly/acXjFJ
![Page 7: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/7.jpg)
![Page 8: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/8.jpg)
Wider determinants of health
![Page 9: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/9.jpg)
![Page 10: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/10.jpg)
World Urban vs Rural Population1950-2030
Source: United Nations, Department of Economic and Social Affairs, Population Division (2006).
![Page 11: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/11.jpg)
World Urban Population, 1950-2005 with Projections to 2020 (in billions)
Source: United Nations, Department of Economic and Social Affairs, Population Division (2006).
![Page 12: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/12.jpg)
![Page 13: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/13.jpg)
Manchester Urban Collaboration on Health
![Page 14: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/14.jpg)
VisionVision
“To perform world class research on urban issues for the benefit of
local populations, building real world evidence”
M U C H Manchester Urban Collaboration on Health
EU Commission
€5 million£1.2 million
![Page 15: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/15.jpg)
Urban Health
Knowledge Centre Network
Future
Teaching/Training on Urban Health
Governments
NGOs
Charities
Industry
Tools
![Page 16: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/16.jpg)
The Importance of COPD
![Page 17: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/17.jpg)
COPD and Public Health Tools
• COPD is a complex disease – public health can offer tools to help with evidence-
based decision making• The following demonstrate the utility of the tools
commonly used in the UK as part of routine public health practice– The first is a needs assessment which maps local
needs, demands and service with the evidence-based literature.
– The second is to use a population impact assessment tool to help prioritise interventions in COPD.
– The third is how to evaluate pharmacists to providing support for evidence-based prescribing in COPD.
![Page 18: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/18.jpg)
Healthcare Needs Assessment Of Chronic Obstructive Pulmonary Disease Services In Trafford
A. Verma1, G. Mates2, C. Franco3, L. Davies3, R. F. Heller1, B. Leahy2.
1 University of Manchester2 Trafford Healthcare NHS Trust3 NHS Trafford
Thorax 2007
![Page 19: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/19.jpg)
17
19
21
23
25
27
29
31
per
cen
tag
e sm
oki
ng
Great
Brit
ain
All Eng
land
North
East
North
Wes
t
Yorks
hire
and t
he H
umbe
r
East M
idlan
ds
Wes
t Midl
ands
East o
f Eng
land
Lond
on
South
Eas
t
South
Wes
t
Wale
s
Scotla
nd
area
Smoking prevalence in Great Britain, England, English Regions, Wales and Scotland
1998 2000 2001 2002 2003 2004 2005 2006
![Page 20: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/20.jpg)
0
50
100
150
200
250
300
350
400
450
engl
and
and
wales
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
year
Smoking Mortality Rates for North West region compared with England and Wales
![Page 21: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/21.jpg)
100 99
47
112141
59
105
204
144
191
72 83
0
50
100
150
200
250
value
england and wales
North W
est SHA
Bolton MCD
Bury MCD
Manchester MCD
Oldham MCD
Rochdale MCD
Salford MCD
Stockport MCD
Tameside MCD
Trafford MCD
Wigan MCD
region
Comparative SMR figures for 2006
Series1
![Page 22: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/22.jpg)
Smoking Attributable DeathsGreater Manchester
0
20
40
60
80
100
120
140
Bolton
Bury
Man
ches
ter
Oldha
m
Rochd
ale
Salfor
d
Stock
port
Tames
ide
Traffo
rd
Wig
an
smokingattributabledeaths
![Page 23: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/23.jpg)
Standardised Hospital PrevalenceGreater Manchester
0
20
40
60
80
100
120
140
Bolto
n
Bury
Man
ches
ter
Oldh
am
Rochd
ale
Salfo
rd
Stock
port
Tames
ide
Traffo
rd
Wig
an
StandardisedHospitalPrevalence
![Page 24: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/24.jpg)
Questionnaire completed by (n=18)
Practice Nurse,
13, 72%
GP, 2, 11%
Both, 2, 11%
Don't Know, 1,
6%
![Page 25: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/25.jpg)
Results
0
2
4
6
8
10
12
14
16
18
01:01 Smokers Clinic 4 week follow up
• 100% recorded smoking status
• 14/18 (74%) of practices• COPD lead• Nursing resources• COPD register
• Only 8/18 (50%) of practices has COPD trained staff
How does the practice offer smoking cessation support? N=18
![Page 26: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/26.jpg)
At risk group targeted for smoking cessation and then screened? N=18
0
1
2
3
4
5
6
7
8
Not targeted orscreened
Targeted but notscreened
Targeted andscreened
0
2
4
6
8
10
12
14
16
Nurses receivedCOPD training
Nurses receivedspirometry
training
Nurses whoperformedSpirometry
• Only 9/18 (50%) of nurses had received any training in COPD
• 15/18 (83.3%) were trained in spirometry
• 10/18 (55.6%) used it
![Page 27: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/27.jpg)
Who has been trained for spirometry?n=16
• 10/18 (56%) checked diagnosis with spirometry• 17/18 (94%) had access to secondary care• 10/18 (56%) had access to a respiratory specialist nurse• 15/18 (83%) had an agreed management plan with the patient• 16/18 (89%) checked inhaler technique
![Page 28: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/28.jpg)
Education and Management n=18
0 5 10 15 20
Info on condition
What to do
Own illness management
Available support
Fluvac
Pneumovac
Review
No
Yes
![Page 29: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/29.jpg)
Using Population Impact Measures In Chronic Obstructive Pulmonary Disease For Prioritisation Of Resources In TraffordA. Verma1,2 I.Gemmell1 L.Davies2 R.F.Heller1
1 University of Manchester2 NHS Trafford
Journal of Public Health Vol. 34, No. 1, pp. 83–89 doi:10.1093/pubmed/fdr026
![Page 30: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/30.jpg)
The Population Health Evidence CycleThe Population Health Evidence Cycle
![Page 31: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/31.jpg)
![Page 32: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/32.jpg)
Number Needed to Treat (NNT) and the populationNumber Needed to Treat (NNT) and the population
![Page 33: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/33.jpg)
Going from the patient to the populationGoing from the patient to the population
• Population Impact Numbers have been designed to take into account the impact of an intervention on the population as a whole
• Number of Events Prevented in your Population (NEPP)
“the number of events prevented by the intervention in your population”
• Size (and characteristics) of your population
• Frequency of the condition in your population
• Baseline risk of death in next year (or whatever other outcome measure you want to use)
• Relative Risk Reduction (from the literature)
• Best practice treatment levels (from guidelines)
• Current treatment levels in your population
![Page 34: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/34.jpg)
NEPP NEPP
N * Pe * [Pd *] BR * RRRN * Pe * [Pd *] BR * RRR
N = no. of people in population of interest
Pe = prevalence of the disease in the population
Pd = Population with disease (not needed)
BR = baseline risk of a cardiac event in 5 years
RRR = relative risk reduction associated with treatment
![Page 35: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/35.jpg)
AimsAims
In line with the new BTS/NICE guidelines in COPD, we
examined the number of admissions prevented in the
Trafford population aged over 65 years by increasing
the uptake of influenza and pneumococcal
vaccination
![Page 36: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/36.jpg)
DataData
• Population size and incidence
– Office of National Statistics
– Trafford PCTs data
• Relative risk reduction from meta-analyses data
– 0.330.33 for fluvac [Kelly et al 2004]
– 0.480.48 for pneumovac [Nichols 1999]
![Page 37: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/37.jpg)
ResultsResults
• The current level of immunisation in
• >65-year olds for fluvac and pneumovac
– 72% and aim to increase this to 90%
• The population size for Trafford
– Total = 225,000
– Aged >65 = 45,000
– Pe = 90% - 72% = 18% or 0.18
– BR is 4.3 hospitalisations/1000 or 0.0043
![Page 38: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/38.jpg)
N * Pe * [Pd *] BR * RRRN * Pe * [Pd *] BR * RRR
Fluvac
45000 * 0.18 * 0.0043 * 0.33
Pneumovac
45000 * 0.18 * 0.0043 * 0.48
![Page 39: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/39.jpg)
An online tool for calculating PIMs has been developed and is available at
www.phsim.man.ac.uk
![Page 40: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/40.jpg)
![Page 41: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/41.jpg)
![Page 42: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/42.jpg)
ButBut• Trafford average LOS for COPD
– 11.1 days• Cost of a bed day
– £300– Without any intervention
![Page 43: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/43.jpg)
Fluvac (95%CI)
Pneumococcal (95% CI)
Pe 0.18 0.18
BR 0.0043 0.0043
RRR 0.33 (0.27-0.38)
0.48(0.16-0.62)
NEPP 11.5 11.5 (9.3 to 13.8)(9.3 to 13.8)
16.7 16.7 (8.3-24.7)(8.3-24.7)
Potential Cost saving*
£38,000£38,000 £56,000£56,000
*The potential cost savings need to be considered in light of other factors e.g. cost of programmes to improve uptake.
![Page 44: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/44.jpg)
ThereforeTherefore
• If we were to increase the vaccine uptake from 72% to 90% in our >65 year population
• we would prevent 11.5 and 16.7 admissions/year at a cost saving of £38,000 and £56,000/year
• Different populations with differing demographics, immunisation rates and baseline risk will have differing results which will influence policy making decisions
![Page 45: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/45.jpg)
ConclusionConclusion
The utility of PIMs is to help prioritise and implement national guidelines based on recent
evidence and local data by comparing the different cost savings afforded by reducing the
number of admission prevented
![Page 46: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/46.jpg)
Are pharmacists reducing COPD’s impact through smoking cessation and assessing inhaled steroid use?
A. Verma1, A. Harrison1, P. Torun1, J. Vestbo1, R. Edwards2, J. Thornton1
1 University of Manchester, UK2 University of Otago, New Zealand
Respir Med. 2012 Feb;106(2):230-4. Epub 2011 Sep 7.
![Page 47: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/47.jpg)
UK Recommendations
• NICE/BTS COPD 2004 guidelines recommend• COPD patients who smoke should be encouraged to stop at
every opportunity• Inhaled corticosteroid should be used only among patients with
moderate to severe COPD• Pharmacists should identify smokers and provide smoking
cessation advice.
• Methods• A self-completion questionnaire was sent to 2080 community
pharmacists from the 2005 pharmacist census database.
![Page 48: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/48.jpg)
Results
• Of the 1051 (50.5%) respondants• 37.1% mentioned COPD as a risk from
smoking most or every time• 54.5% sometimes or rarely• 19.6% routinely asked about smoking status
when dispensing COPD medication
![Page 49: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/49.jpg)
• Pharmacists with more than 20 years experience were more likely to have read the Guideline compared to pharmacists with 10 years or less (OR: 1.54; 95% CI: 1.13 to 2.10)
• Pharmacists who had read the NICE Guideline (46.8%) were around twice as likely to mention COPD as a risk of smoking, ask about COPD if inhaled corticosteroids were dispensed and ask about smoking routinely if COPD medication was dispensed. (p<0.005).
Results
![Page 50: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/50.jpg)
Yes%
(95% CI)
No%
(95% CI)
Need to improve knowledge on COPD management
81.1(78.6 to 83.4)
18.9(16.6 to 21.4)
Training would be beneficial 91.5(89.7 to 93.1)
8.5(6.9 to 10.3)
Table-1: Community pharmacists’ opinions on improving their knowledge further
![Page 51: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/51.jpg)
Read NICE COPD Guideline
Yes %
(95% CI)
No%
(95% CI)
Ask about smoking routinely if COPD medication dispensed (n=1036)
27.2(23.4 to 31.4)
12.9(10.3 to 15.9)
Ask at least sometimes whether COPD/Asthma diagnosed if inhaled corticosteroids dispensed (n=1041)
11.0(8.5 to 14.2)
6.0(4.3 to 8.3)
Mention COPD at least sometimes as a risk from smoking (n=1042)
49.5(45.1 to 53.9)
22.1(18.7 to 25.8)
Table-2: Relationship between reading the COPD Guideline and compliance with the recommendations among community pharmacists
![Page 52: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/52.jpg)
• NICE guidelines encourage some community pharmacists to carry out smoking cessation and educational interventions– We recommend further dissemination to
encourage other pharmacists of their role
Conclusions
![Page 53: Dra. arpana verma mesa pacap](https://reader034.vdocuments.mx/reader034/viewer/2022052602/55a15a0f1a28ab350e8b4828/html5/thumbnails/53.jpg)
Conclusions for the multi-modal approach
• Resources are limited and reducing in many aspects of healthcare
• A multi-modal approach for COPD is essential• Baseline activity and needs/demands• Prioritisation of interventions• Evaluation of interventions